Article
Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.
BMC cancer - 21 Feb 2022
Zeng Ya, Guo Tiantian, Zhou Yue, Zhao Yang, Chu Li, Chu Xiao, Yang Xi, Ni Jianjiao, Zhu Zhengfei
Abstract excerpt
BACKGROUND: The clinical features, survival outcomes and patterns of treatment failure of advanced non-small cell lung cancer (NSCLC) patients harboring distinct subtypes of EGFR mutations and receiving first-line EGFR tyrosine kinases inhibitor (TKIs) are not fully understood. METHODS: Consecutive metastatic EGFR-mutant NSCLC patients receiving first-line EGFR-TKIs from October 2010 to March 2020 were enrolled...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.